Senores Pharmaceuticals Share Price

    696.5
    -5.15 (-0.73%)
    SENORES • 02 Sep, 2025 | 03:29 PM
    Buy
    with MTF at2.86xleverage
    The current prices are delayed, login or Open Demat Account for live prices.

    Senores Pharmaceuticals Stock Performance

    1W Return-1.52
    1Y Return0.00
    Today's Low692.1
    Prev. Close701.65
    Mkt Cap (Cr.)3,207.63
    1M Return4.68
    3Y Return0.00
    52-Week High737.85
    Open708.85
    PE Ratio0.00
    6M Return31.29
    Today's High709.5
    52-Week Low435.25
    Face Value10

    Senores Pharmaceuticals Company background

    Founded in: 2017
    Managing director: SWAPNIL JATINBHAI SHAH
    Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the midmarket range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company is planning to raise money from public through IPO by issue and allotment of 2,700,000 Equity Shares through Offer for Sale and Rs 500 Crores equity funds through Fresh Issue.

    Senores Pharmaceuticals Financial Highlights


    Senores Pharmaceuticals reported a Q1FY26 revenue of ₹137.99 crore, up 92.1% YoY, with net profit increased 78.4% to ₹21.18 crore. For the full year FY2025–2026, revenue reached ₹417.51 crore and profit touched at ₹58.34 crore. As of Jun '25, Senores Pharmaceuticals’s market capitalisation stood at ₹3,207.63 crores. Shareholding as of Jun '25 shows promoters holding 45.8%, with FIIs at 3.7%, DIIs at 9.5%, and public at 41%.

    As of 02 Sep, 2025, Senores Pharmaceuticals share price is ₹696.5. The stock opened at ₹708.8 and had closed at ₹701.6 the previous day. During today’s trading session, Senores Pharmaceuticals share price moved between ₹692.10 and ₹709.50, with an average price for the day of ₹700.80. Over the last 52 weeks, the stock has recorded a low of ₹435.25 and a high of ₹737.85. In terms of performance, Senores Pharmaceuticals share price has increased by 27.8% over the past six months and has increased by 24.38% over the last year.
    Read More
    View details of Market Depth

    Senores Pharmaceuticals Fundamental

    Market Cap (in crs)

    3,207.63

    Face Value

    10

    Turnover (in lacs)

    968.22

    Key Metrics

    Qtr Change %
    60.02% Gain from 52W Low
    34.4
    Dividend yield 1yr %
    0

    Senores Pharmaceuticals Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Senores Pharmaceuticals Quarterly Revenue
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    137.99 Cr
    114.21 Cr
    103.02 Cr
    180.21 Cr
    0.8 Cr
    Senores Pharmaceuticals Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022
    417.51 Cr
    217.34 Cr
    39.02 Cr
    14.63 Cr
    Senores Pharmaceuticals Quarterly Net Profit/Loss
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    21.18 Cr
    17.97 Cr
    16.43 Cr
    23.83 Cr
    0.11 Cr
    Senores Pharmaceuticals Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022
    58.34 Cr
    32.71 Cr
    8.43 Cr
    0.99 Cr

    Senores Pharmaceuticals Result Highlights

    • Senores Pharmaceuticals Ltd reported a 35.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 17350.6%.

    • Its expenses for the quarter were down by 40.3% QoQ and up 16791.2% YoY.

    • The net profit decreased 35.2% QoQ and increased 19154.5% YoY.

    • The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 4.6 during Q1FY26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Senores Pharmaceuticals Shareholding Pattern

    Promoter
    45.8%
    Foreign Institutions
    3.7%
    Mutual Funds
    3%
    Domestic Institutions
    9.5%
    Public
    41%
    Promoter
    45.8%
    Foreign Institutions
    4.2%
    Mutual Funds
    3.2%
    Domestic Institutions
    9.6%
    Public
    40.4%
    Promoter
    45.8%
    Foreign Institutions
    4.2%
    Mutual Funds
    5%
    Domestic Institutions
    11.8%
    Public
    38.2%

    Senores Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    696.5
    Current Price
    Bullish Moving Averages
    9
    Bearish Moving Averages
    5
    5Day EMA
    699.30
    10Day EMA
    698.20
    12Day EMA
    696.60
    20Day EMA
    687.60
    26Day EMA
    679.40
    50Day EMA
    648.50
    100Day EMA
    611.60
    EMA
    5Day SMA
    698.70
    10Day SMA
    704.50
    20Day SMA
    688.60
    30Day SMA
    678.50
    50Day SMA
    641.30
    100Day SMA
    582.10
    150Day SMA
    573.90
    SMA
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    81951 Rs
    149044 Rs
    Week Rs
    114819 Rs
    233023 Rs
    Month Rs
    135312 Rs
    340265 Rs
    699.37
    Pivot
    Resistance
    First Resistance
    706.63
    Second Resistance
    716.77
    Third Resistance
    724.03
    Support
    First Support
    689.23
    Second support
    681.97
    Third Support
    671.83
    Relative Strength Index
    55.46
    Money Flow Index
    71.90
    MACD
    17.19
    MACD Signal
    20.50
    Average True Range
    28.44
    Average Directional Index
    20.99
    Rate of Change (21)
    1.10
    Rate of Change (125)
    22.71
    Name
    Holding Percent
    Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund
    1.39
    Mahindra Manulife Large & Mid Cap Fund
    1.11
    Astorne Capital Vcc - Arven
    2.16
    Aditya Birla Sun Life Insurance Company Limited
    4.05

    Senores Pharmaceuticals Latest News

    02 SEP 2025 | Tuesday

    Senores Pharmaceuticals Ltd - 544319 - Re-Scheduling Of The Analyst / Institutional Investor Meetings Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations 2015

    01 SEP 2025 | Monday

    Senores Pharmaceuticals Ltd - 544319 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    01 SEP 2025 | Monday

    Senores Pharmaceuticals Ltd - 544319 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    View More

    Senores Pharmaceuticals Share Price FAQs

    Senores Pharmaceuticals share price is ₹696.5 in NSE and ₹695.95 in BSE as on 2/9/2025.

    Senores Pharmaceuticals share price in the past 1-year return was 0. The Senores Pharmaceuticals share hit a 1-year low of Rs. 435.25 and a 1-year high of Rs. 737.85.

    The market cap of Senores Pharmaceuticals is Rs. 3207.63 Cr. as of 2/9/2025.

    The PE ratios of Senores Pharmaceuticals is 0 as of 2/9/2025.

    The PB ratios of Senores Pharmaceuticals is 4.52 as of 2/9/2025

    The Mutual Fund Shareholding in Senores Pharmaceuticals was 3% at the end of 2/9/2025.

    You can easily buy Senores Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Senores Pharmaceuticals share price is ₹737.85 and ₹435.25 as of 2/9/2025.

    The earnings per share (EPS) of Senores Pharmaceuticals stood at 4.6 during Q1FY26.

    Please be aware that Senores Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Open Demat Account
    +91 -

    Popular Stocks
    58.25
    +0.39 (+0.67%)
    122.99
    +2.45 (+2.03%)
    684.40
    -5.75 (-0.83%)
    2,274.20
    -10.00 (-0.44%)
    144.14
    +1.63 (+1.14%)
    331.85
    +16.15 (+5.12%)
    158.39
    +2.22 (+1.42%)
    322.40
    +1.30 (+0.40%)
    376.60
    +2.70 (+0.72%)
    386.05
    +5.50 (+1.45%)
    Top Gainers
    286.70
    +6.85 (+2.45%)
    1,100.80
    +25.10 (+2.33%)
    1,200.90
    +26.50 (+2.26%)
    336.30
    +5.60 (+1.69%)
    158.39
    +2.22 (+1.42%)
    Top Losers
    3,234.50
    -80.90 (-2.44%)
    1,253.70
    -26.20 (-2.05%)
    1,942.50
    -26.10 (-1.33%)
    1,394.20
    -16.80 (-1.19%)
    2,540.00
    -30.20 (-1.18%)
    Open Demat Account
    +91 -